The FDA has temporarily suspended clinical trials of the product of its own corporation VіаСеll
- Autores: Stankov D.S., Bersenyev A.V.
- Edição: Nº 1 (2006)
- Páginas: 37-37
- Seção: Cell technology
- ##submission.dateSubmitted##: 18.01.2023
- ##submission.dateAccepted##: 18.01.2023
- ##submission.datePublished##: 06.03.2023
- URL: https://genescells.ru/2313-1829/article/view/124245
- DOI: https://doi.org/10.23868/gc124245
- ID: 124245
Citar
Texto integral
![Acesso aberto](https://genescells.ru/lib/pkp/templates/images/icons/text_open.png)
![Acesso é fechado](https://genescells.ru/lib/pkp/templates/images/icons/text_unlock.png)
![Acesso é fechado](https://genescells.ru/lib/pkp/templates/images/icons/text_lock.png)
Texto integral
![Acesso é fechado](https://genescells.ru/lib/pkp/templates/images/icons/text_lock.png)
Sobre autores
D. Stankov
Autor responsável pela correspondência
Email: redaktor@celltranspl.ru
Rússia
A. Bersenyev
Email: redaktor@celltranspl.ru
Rússia
Bibliografia
- Gluckman E., Broxmeyer H.A., Auerbach A.D. et al. Hematopoietic reconstitution in a patient with Fanconi’s anemia by means of umbilical-cord blood from an HLA-identical sibling. N. Engl. J. Med. 1989; 321: 1174-8.
- Cohen Y., Nagler A. Umbilical cord blood transplantation - how, when and for whom? Blood Rev. 2004; 18: 167-79.
Arquivos suplementares
![](/img/style/loading.gif)